Cohance Lifesciences Files SEBI Compliance Certificate for Q3 FY26
Cohance Lifesciences Limited filed a certificate under SEBI regulations for the quarter ended December 31, 2025. The certificate confirms dematerialization/rematerialization of securities, as furnished to stock exchanges by the Registrar and Share Transfer Agents, KFin Technologies Limited.
This is a standard regulatory filing for every listed company and does not involve any new business development, financial results, or corporate actions that would significantly impact the company's stock or operations.
The announcement is a routine compliance filing related to SEBI regulations and does not contain any material financial or business updates that would impact the company's sentiment.
Cohance Lifesciences Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025.
The certificate confirms that the details of securities dematerialized or rematerialized during the said period have been furnished to all the stock exchanges where the company's shares are listed. This information has been provided by KFin Technologies Limited, the company's Registrar and Share Transfer Agents.
The announcement was made on January 5, 2026, and is a routine compliance filing.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.